Laser zaps penile scar tissue in early trial
NCT ID NCT07177833
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 1 trial tests whether a fractional CO2 laser can safely reduce the scar tissue that causes penile curvature in Peyronie's disease. Sixty men with stable, chronic disease will receive three laser sessions over 18 weeks. The main goal is to check for side effects, but researchers will also measure changes in curvature and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fractional CO2 laser
What this could lead to
If it works, this could offer a non-invasive, low-risk option to reduce penile curvature and improve quality of life for men with Peyronie's disease.
What could go wrong
This is a very early phase 1 trial focused on safety, not yet on effectiveness. The laser may not work better than a sham device, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEYRONIES DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Ottawa Hospital
RECRUITINGOttawa, Ontario, K1Y4E9, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact